Bart Wuurman

Bart Wuurman

Apaxen

---

Bart is a biotech CEO with over 30 years’ experience in innovative drug
development, biotech financing, business development and licensing. He
has extensive experience in working with R&D based companies in
several therapeutic areas, including cancer, inflammatory diseases and
fibrosis. Bart Wuurman has contributed to successful biotech company
exits in the UK and in the Netherlands and he was responsible for
pharma licensing deals worth over $700 million. Bart was CEO of De
Novo pharmaceuticals (UK), AM-Pharma (NL), Lanthio Pharma (NL) and
Lyramid (Australia) and is Director of Hercules Pharmaceuticals. Bart was
also Managing Director of DDF Ventures, a life-science focused venture
fund with a portfolio of start-up companies in The Netherlands.